Massachusetts Financial Services Co. MA Sells 42,877 Shares of CeriBell, Inc. $CBLL

Massachusetts Financial Services Co. MA trimmed its holdings in shares of CeriBell, Inc. (NASDAQ:CBLL) by 7.8% during the 4th quarter, Holdings Channel reports. The fund owned 508,456 shares of the company’s stock after selling 42,877 shares during the period. Massachusetts Financial Services Co. MA’s holdings in CeriBell were worth $11,150,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in CeriBell during the 4th quarter worth about $145,000. JPMorgan Chase & Co. grew its holdings in CeriBell by 8.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock worth $4,724,000 after acquiring an additional 31,177 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new position in CeriBell during the 3rd quarter worth about $135,000. Millennium Management LLC grew its holdings in CeriBell by 41.8% during the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock worth $7,657,000 after acquiring an additional 196,299 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in CeriBell by 87.1% during the 3rd quarter. Bank of America Corp DE now owns 135,783 shares of the company’s stock worth $1,560,000 after acquiring an additional 63,215 shares in the last quarter.

Insider Activity at CeriBell

In related news, VP David Foehr sold 5,556 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $20.00, for a total value of $111,120.00. Following the completion of the transaction, the vice president directly owned 18,900 shares of the company’s stock, valued at $378,000. This trade represents a 22.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Josef Parvizi sold 16,714 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $20.27, for a total transaction of $338,792.78. Following the completion of the transaction, the director directly owned 722,652 shares of the company’s stock, valued at $14,648,156.04. The trade was a 2.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 130,571 shares of company stock valued at $2,411,026. Company insiders own 20.10% of the company’s stock.

CeriBell Stock Performance

Shares of CeriBell stock opened at $20.74 on Friday. The firm has a market capitalization of $780.67 million, a P/E ratio of -14.11 and a beta of 0.94. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The company has a 50 day moving average price of $19.03 and a 200 day moving average price of $17.85. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $24.33.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm had revenue of $24.78 million during the quarter, compared to analyst estimates of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. Sell-side analysts expect that CeriBell, Inc. will post -2.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on CBLL. Weiss Ratings reissued a “sell (d-)” rating on shares of CeriBell in a research report on Monday, April 6th. BTIG Research reissued a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.